PRLD

Prelude Therapeutics Incorporated

2.03

USD

PRLD Earnings Reports

Positive Surprise Ratio

PRLD beat 15 of 21 last estimates.

71%

Next Report

Date of Next Report

Mar 09, 2026

Estimate for Q4 25 (Revenue/ EPS)

$35.70M

-$0.02

Implied change from Q3 25 (Revenue/ EPS)

+449.23%

-92.31%

Implied change from Q4 24 (Revenue/ EPS)

+792.50%

-94.74%

Prelude Therapeutics Incorporated earnings per share and revenue

On Nov 12, 2025, PRLD reported earnings of -0.26 USD per share (EPS) for Q3 25, beating the estimate of -0.37 USD, resulting in a 30.22% surprise. Revenue reached 6.50 million, compared to an expected --, with a 0.00% difference. The market reacted with a +8.89% price change (close before vs. close after earnings).

Looking ahead to Q4 25, 5 analysts forecast an EPS of -0.02 USD, with revenue projected to reach 35.70 million USD, implying an decrease of -92.31% EPS, and increase of 449.23% in Revenue from the last quarter.

FAQ

What were Prelude Therapeutics Incorporated's earnings and revenue for the latest quarter Q3 2025?

For Q3 2025, Prelude Therapeutics Incorporated reported EPS of -$0.26, beating estimates by 30.22%, and revenue of $6.50M, 0% as expectations.

How did the market react to Prelude Therapeutics Incorporated's Q3 2025 earnings?

The stock price moved up 8.89%, changed from $1.35 before the earnings release to $1.47 the day after.

When is Prelude Therapeutics Incorporated expected to report next?

The next earning report is scheduled for Mar 09, 2026.

What are the forecasts for Prelude Therapeutics Incorporated's next earnings report?

Based on 5 analysts, Prelude Therapeutics Incorporated is expected to report EPS of -$0.02 and revenue of $35.70M for Q4 2025.

Which companies are reporting earnings today?

Check FXEmpire's Earnings Calendar for today's list of reporting companies.